The global health landscape faces a growing challenge with the expansion of Mpox outbreaks, prompting GeoVax Labs, Inc. to highlight the urgent need for diversified vaccine supplies. The European Medicines Agency (EMA) has endorsed a streamlined development pathway for GeoVax's GEO-MVA vaccine candidate, allowing for a single Phase 3 immuno-bridging trial to support a Marketing Authorisation Application. This approach significantly reduces development time while maintaining regulatory standards, offering a timely solution to the escalating Mpox crisis.
Recent data from the Airfinity July 2025 Mpox Report underscores the severity of the situation, with Clade I Mpox cases now detected across all continents, including new outbreaks in China, the United Kingdom, Italy, and the U.S. The report also highlights the risk of vertical transmission of the virus from mother to child during pregnancy, emphasizing the need for vaccines with broader safety data and global availability.
GeoVax's GEO-MVA vaccine is positioned as a scalable and strategic alternative to current MVA-based vaccines, with plans to transition to a modernized manufacturing system for lower-cost, U.S.-based production. The company is engaging with global health organizations and governments to explore advance purchase agreements and manufacturing alliances, aiming to rapidly deploy GEO-MVA in affected regions.
The endorsement from EMA and the accelerating global spread of Mpox strains underscore the critical importance of GeoVax's efforts. With the world's Mpox vaccine infrastructure under strain, the development of GEO-MVA represents a vital step towards ensuring global health security and resilience against emerging infectious disease threats.
